A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
← catalyst calendarNCT04008797 · readout in 223 d
Sponsored by Eisai Inc. (industry) · 4523.T — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
301estimated
Sites
106
Countries
Canada, China, Denmark +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-07-11 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2019-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Endometrial Neoplasms
- Neoplasms
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Colorectal Neoplasms
Interventions
- Drug: E7386
- Drug: Lenvatinib — also filed as Lenvima, E7080
- Drug: Doxorubicin
- Drug: Paclitaxel
Primary outcomes
what the primary-completion date above is the date OFDose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs)
measured Cycle 0 (Cycle 0 length=6 or 7 days) up to Cycle 1 (Cycle 1 length=28 days)
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Up to 30 days after the last dose of study drug or before initiating post anti-cancer treatment (up to approximately 90 months)
Dose Optimization Part: Objective Response Rate (ORR) per RECIST 1.1 by Investigator Assessment
measured From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 90 months)
Publications
- PMID 40986544 — linked by the registry
- PMID 40318924 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed